IFNA1 and chronic obstructive pulmonary disease: The macrolide antibiotic Azithromycin has been demonstrated to influence immune parameters, such as increasing antiviral IFN expression in both healthy and in virus‐infected cells, and to exert antiviral and anti‐inflammatory actions, thereby reducing exacerbations in chronic obstructive pulmonary disease (COPD) [50, 51].